Portfolio of Companies
Growcorp has invested in a strong portfolio of companies in the biosciences sector. Growcorp has an experienced management team with successful international experience in Bioscience, IP, investment, marketing and business development.
Fluorocap Limited
Fluorocap originates from the National Centre for Sensors Research at Dublin City University and is commercialising a new and more efficient Biochip for use by the Biotech and Life Science Industries.
Merrion is a specialty pharmaceutical company based upon proprietary technologies for oral drug delivery acquired from the Elan Corporation in 2003. It has multiple market-ready, advanced oral drug delivery technologies with several significant products already proven in human clinical trials. In addition it has a research pipeline of novel tissue targeting drug delivery technologies providing future product solutions for the oral delivery of CNS drugs and vaccines.
Gas Sensor Solutions originated in the National Centre for Sensors Research at Dublin City University. It has a strong portfolio of innovative gas sensor technologies to solve unmet needs across a wide range of valuable applications, including packaging permeability testing, food quality, oxygen sensitive package integrity, medical and environmental analysis.
Copyright 2007 Growcorp Group. All Rights Reserved.
Office: Growcorp Group Limited, 3015 Lake Drive, Citywest Campus, Citywest, Dublin 24 | Telephone: +353 1 4661000 | Fax: +353 1 4661002
NEUtekBio was founded in 2001 to commercialise novel diagnostic and prognostic assays aimed at increasing the efficacy of critical drug treatments involving Interferons and other Cytokines.
Pharmatrin Limited
Pharmatrin is developing a novel class of therapeutics known as indane dimers. The target therapeutic areas are organ transplant rejection and autoimmune diseases. The Company is based in Trinity College Dublin.
Orakine Limited
Orakine Limited was formed to commercially exploit the proprietary technology developed to take advantage of natural cytokine therapy through simple contact with the oromucosal tissue and subsequent cellular activation and trafficking. This patented and novel technology will revolutionise the 12 billion cytokine pharmaceutical market.
